Clinical Trial Update: Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP) [Phase 4]

View source ↗

Summary

Phase 4 study assessing the efficacy and safety of Ceftazidime-Avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Ceftazidime-Avibactam (CAZ-AVI) (ceftazidime-avibactam)

Snippet

Sponsor: Pfizer | Conditions: Hospital-Acquired Pneumonia | Phase 4 | Status: COMPLETED | Results posted: 2024-09-19